Overview

Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma

Status:
Completed

Trial end date:
2019-11-26

Target enrollment:

Participant gender:

Summary

To establish a recommended dose of BAY1862864 Injection and to investigate how the study drug acts in the body, on the cancer cells and how safe it is in patients with advanced non-Hodgkin's lymphoma (NHL)

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Treatments:

Radiopharmaceuticals